From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody–Drug Conjugates
- 1Department of Chemistry, Graduate School, Soongsil University, Seoul 06978, Republic of Korea
- 2AI-Bio Convergence Research Institute, Soongsil University, Seoul 06978, Republic of Korea
Abstract
Bispecific antibody–drug conjugates (bsADCs) are being developed to address limitations of conventional ADCs, including heterogeneous antigen expression, insufficient tumor–normal discrimination, and suboptimal intracellular trafficking. This review evaluates bsADCs from a preclinical-to-clinical translational perspective and defines the evidence needed to justify the added complexity of bispecific design. A structured search of PubMed/MEDLINE, Embase, Web of Science, Scopus, clinical-trial registries, and major oncology conference proceedings was conducted through 29 July 2026. Dual-antigen bsADCs were classified as coverage-oriented, co-expression-dependent, trafficking-assisted, or multifunctional, while biparatopic ADCs were considered mechanistically related comparators. Dual recognition can broaden tumor coverage, enhance avidity-dependent selectivity, improve intracellular trafficking, or add biological functions. These effects depend on target-pair biology, molecular format, valency, epitope geometry, arm affinity, linker–payload properties, drug-to-antibody ratio, pharmacokinetics, normal-tissue exposure, manufacturability, and biomarker feasibility. Clinically, izalontamab brengitecan supports the feasibility of selected architectures, whereas MEDI4276 and TQB2102 illustrate how complete molecular design shapes therapeutic index. We propose an integrated translational framework and functional design parsimony, defined as selecting the least complex ADC architecture capable of achieving the intended biological and translational objective. Bispecificity should be used only when it provides a demonstrable advantage over a simpler ADC design.
Related
- Natural products targeting mitochondrial homeostasis: a four-dimensional framework integrating dynamics, mitophagy, pharmacokinetics, and translational safety
- Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.
- 914 Dual-antigen targeting via a PMPC-engineered bispecific ADC overcomes tumor heterogeneity and enhances anti-tumor efficacy in advanced ovarian cancer
- 891 Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma
- Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice
BibTeX
@article{kim2026from,
title = {{From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody–Drug Conjugates}},
author = {Jun Kim and Seounghun Kang},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198748},
url = {https://www.mdpi.com/1422-0067/27/19/8748},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody–Drug Conjugates
AU - Jun Kim
AU - Seounghun Kang
PY - 2026
DA - 2026/09/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198748
UR - https://www.mdpi.com/1422-0067/27/19/8748
AB - Bispecific antibody–drug conjugates (bsADCs) are being developed to address limitations of conventional ADCs, including heterogeneous antigen expression, insufficient tumor–normal discrimination, and suboptimal intracellular trafficking. This review evaluates bsADCs from a preclinical-to-clinical translational perspective and defines the evidence needed to justify the added complexity of bispecific design. A structured search of PubMed/MEDLINE, Embase, Web of Science, Scopus, clinical-trial registries, and major oncology conference proceedings was conducted through 29 July 2026. Dual-antigen bsADCs were classified as coverage-oriented, co-expression-dependent, trafficking-assisted, or multifunctional, while biparatopic ADCs were considered mechanistically related comparators. Dual recognition can broaden tumor coverage, enhance avidity-dependent selectivity, improve intracellular trafficking, or add biological functions. These effects depend on target-pair biology, molecular format, valency, epitope geometry, arm affinity, linker–payload properties, drug-to-antibody ratio, pharmacokinetics, normal-tissue exposure, manufacturability, and biomarker feasibility. Clinically, izalontamab brengitecan supports the feasibility of selected architectures, whereas MEDI4276 and TQB2102 illustrate how complete molecular design shapes therapeutic index. We propose an integrated translational framework and functional design parsimony, defined as selecting the least complex ADC architecture capable of achieving the intended biological and translational objective. Bispecificity should be used only when it provides a demonstrable advantage over a simpler ADC design.
SN - 1422-0067
ER -